AVH 0.78% $2.60 avita medical inc.

Ann: AVITA Receives FDA IDE Approval to Evaluate RECELL for Vitil, page-6

  1. 1,071 Posts.
    lightbulb Created with Sketch. 179
    great achievement and milestone, Based on the
    outcomes of the feasibility study, we anticipate proceeding with a pivotal clinical trial to pursue FDA approval of the RECELL System as a cell-based repigmentation treatment option for stable vitiligo.
 
watchlist Created with Sketch. Add AVH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.